Loading patent…
AssigneesCouncil of Scientific, Industrial Research Limited
InventorsSantu Bandyopadhyay, Bikas Chandra Pal, Samir Bhattacharyay, Swapan Mondal, Chhabinath Mandal, Aditya Konar, Keshab Chandra Roy, Tanusree Biswas, Gautam Bandyopadhyay
Estimating the term…
The present invention relates to a pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid such as neochlorogenic acid (5-O-caffeoyl quinic acid), cryptochlorogenic acid (4-O-Caffeoyl quinic acid), 3-O-(3′-methylcaffeoyl) quinic acid and 5-O-(Caffeoyl-4′-methyl) quinic acid and/or its salts such as sodium, potassium and ammonium together with pharmaceutically acceptable additives.
A pharmaceutical composition useful for treating chronic myeloid leukemia where Bcr-Abl kinase is constitutively expressed in animals and humans, said composition comprising an effective amount of analogs of chlorogenic acid and/or its salts along with pharmaceutically acceptable additives.
A method of treating chronic myeloid leukemia CML where Bcr-Abl kinase is constitutively expressed in animals and humans, said method comprising administering a pharmaceutical composition comprising an effective amount of analogs of chlorogenic acid and/or its salts along with pharmaceutically acceptable additives.
Dependencies are inferred from the claim text.